Description

OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel[1][2].—COVID-19-immunoregulation–C43H71N9O12—-[1]François P, et al. Phenotypic model for early T-cell activation displaying sensitivity, specificity, and antagonism. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E888-97.|[2]Kamalov M,et al. Ovalbumin Epitope SIINFEKL Self-Assembles into a Supramolecular Hydrogel. Sci Rep. 2019 Feb 25;9(1):2696.–148274-82-2–906.08—-CC(C)C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H](CC1=CC=CC=C1)NC(CNC([C@H]([C@@H](C)CC)NC([C@H]([C@@H](C)CC)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–10 mM in DMSO–Others—-Others–Peptides